Related Experiment Video

Updated: Oct 21, 2025

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

14.0K

Chemokine Receptor Antagonists: Role in Oncology

Sean Kraus1, Thomas Kolman1, Austin Yeung1

  • 1Division of Hematology, Oncology and Palliative Care, Department of Medicine, University of WI-Madison, Madison, WI, USA.

Current Oncology Reports
|September 4, 2021
PubMed
Abstract

Insights

Chemokine receptor antagonists show promise for cancer treatment by modulating the tumor microenvironment. Further research is needed to optimize their use in improving patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Chemokine receptors and their ligands influence immune cell infiltration into the tumor microenvironment.
  • These receptors are emerging as critical targets for novel cancer therapies.
  • Dysregulation of chemokine signaling contributes to tumor progression and immune evasion.

Purpose of the Study:

  • To evaluate the clinical potential of chemokine receptor antagonists in cancer treatment.
  • To explore the role of chemokine receptor targeting in overcoming treatment resistance.
  • To assess the therapeutic promise of modulating immune cell trafficking in the tumor microenvironment.

Main Methods:

  • Review of pre-clinical research and clinical trial data on chemokine receptor antagonists.
  • Analysis of the impact of specific chemokine receptor blockade on tumor immunity.
  • Investigation of strategies to selectively inhibit detrimental chemokine pathways.

Main Results:

  • Chemokine receptor antagonists demonstrate significant promise in pre-clinical models and early clinical trials.
  • Targeting specific chemokine receptors can alter immune cell composition within the tumor.
  • Inhibiting receptors that recruit suppressive cells while preserving immune-supportive ones is a key strategy.

Conclusions:

  • Chemokine receptor antagonists represent a promising therapeutic strategy for various cancers.
  • Selective targeting of chemokine receptors holds potential for enhancing anti-tumor immunity.
  • Further research is warranted to fully realize the clinical benefits of these agents for patients.
Keywords:
CancerChemokine receptor antagonistOncology

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.1K
Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System10:25

Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System

Published on: September 20, 2019

7.1K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
303
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
551
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.3K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
392
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K